within Pharmacolibrary.Drugs.ATC.A;

model A16AX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 2.777777777777778e-06,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>AnetholeTrithione</td></tr><tr><td>ATC code:</td><td>A16AX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Anethole trithione is a synthetic compound previously used as a choleretic agent to stimulate bile secretion. It has also been investigated for the treatment of dry mouth (xerostomia) in patients with various medical conditions, including Sj√∂gren's syndrome, and as an adjunct therapy in some cancer indications. Its clinical use today is very limited or largely discontinued in most countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a healthy adult oral administration; no direct clinical PK study available for anethole trithione.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end A16AX02;
